Immunoprophylaxis. Guidelines (second edition)

Immunoprophylaxis is one of the most effective tools for reducing morbidity and mortality from infectious diseases. In the context of global epidemiological challenges and increased population mobility, the issues of managing immunization, proper patient selection, safety and effectiveness of vaccination are of particular importance.

The document systematizes modern approaches to organizing and conducting vaccination of adults. It includes sections on planning and vaccination techniques, contraindications and "false contraindications", features of vaccination against specific infections (influenza, pneumococcal infection, hepatitis, diphtheria, tetanus, poliomyelitis, measles, rubella, etc.), as well as vaccination in pregnant women and military personnel. Particular attention is paid to the registration and treatment of post-vaccination reactions and complications, and the costeffectiveness of vaccination.

The guidelines are intended for general practitioners, infectious disease specialists, epidemiologists, pediatricians, and public health specialists.

1. Zvereva VV, Semenova BF, Khaitova RM. Vaccines and vaccination: national guidelines. Moscow: GEOTAR-Media, 2011. 880 p. (In Russ.)

2. Zvereva BB, Khaitova RM. Vaccines and vaccinations. National guideline. Short edition. 2014. 640 p. (In Russ.)

3. Tarasova AA, Lukushkina EF, Kostinov MP, et al. Vaccination prevention. Nizhny Novgorod: Publishing Salon of IP Gladkova O.V., 2016. 103 p. (In Russ.)

4. Kostinov MP, Chuchalin AG. Guidelines for clinical immunology in respiratory medicine. 1st ed. Vol. 2016. Moscow: ATMO LLC. 126 p. (In Russ.)

5. Chuchalin AG, Yasnetsova VV. Federal Guidelines on the use of medicines (formulary system, reference edition). Moscow: Vidox LLC, 2016. 745-768 p. (In Russ.)

6. Tatochenko VK, Ozeretskovsky ON. Immunoprophylaxis. 14th ed. Moscow: Pediatrician, 2020. 384 p. (In Russ.)

7. Namazova-Baranova LS, Briko NI, Feldblum IV. Vaccines and immunoprophylaxis in the modern world. A guide for doctors. Pediatrician. Moscow, 2021. 648 p. (In Russ.)

8. Briko NI, Feldblum YV. The modern concept of vaccine prevention development in Russia. Epidemiology and vaccine prevention. 2019;18(5):4-13. (In Russ.)

9. Feldblum IV, Zueva LP, Aslanov BI. Vaccine prevention in children and adults: A guide for doctors. GEOTAR-Media. St.Petersburg, 2023. 288 p. (In Russ.)

10. Chuchalin AG, Bilichenko TI, Osipova GL. Vaccinoprophylaxis of respiratory diseases in the framework of primary health care for the population. Clinical recommendations. Pulmonology. 2015;25(2):1-19. (In Russ.)

11. Kostinov MP, Zvereva BB. Vaccination against hepatitis B, influenza and rubella in adult patients with chronic diseases. Guide. Moscow: MDV; 196 p. (In Russ.)

12. Protasov AD, Zhestkov AB, Lavrentieva NE, et al. The effect of complex vaccination against pneumococcal, hemophilic type b infections and influenza in patients with chronic obstructive pulmonary disease. Journal of Microbiology, Epidemiology and Immunobiology. 2011;88(4):80-4. (In Russ.)

13. Kostinov MP. Vaccination of adults with bronchopulmonary pathology. A guide for doctors. Moscow: Art Studio Constellation, 2013. 112 p. (In Russ.)

14. Cherdantsev AP, Kuselman AI, Sinitsyna MN, et al. To study the clinical safety of influenza vaccination in pregnant women. Medical almanac. 2011;17(4):120-2. (In Russ.)

15. Bukhtiyarov IV, Briko NI, Roslaya NA, et al. Vaccination of the working population is a guide for doctors. Moscow: Medical Information Agency, 2019. 189 p. (In Russ.)

16. Zverev BB, Kostinov MP, Cherdantsev AP. Vaccination of pregnant women against influenza: Federal clinical guidelines. Moscow; 42 p. (In Russ.)

17. Kostinov MP. Vaccination of children with impaired health. A practical guide for doctors. 4th ed. Moscow: Medicine for All, 2013. 432 p. (In Russ.)

18. Briko NI, Simonova EG, Kostinov MP, et al. Immunoprophylaxis of pneumococcal infections. Nizhny Novgorod: Remedium Privolzhye, 2013. 278 p. (In Russ.)

19. Kostinov MP, Tarasova AA. Vaccination of pneumococcal infection and influenza in autoimmune diseases: a guide for doctors. Moscow: MDV Publishing House, 2009. 252 p. (In Russ.)

20. Kostinov MP. Expansion of the complex of therapeutic and preventive measures for bronchial asthma in children with the use of vaccines "PNEUMO 23" and "AktHIB". A manual for doctors. Moscow: Medicine for All, 2004. 36 p. (In Russ.)

21. Garashchenko TI, Kostinov MP, Ilyenko LI, et al. Preventive and therapeutic use of hemophilic and pneumococcal vaccines in frequently and long-term ill children with recurrent otitis media. Issues of modern pediatrics. 2006;5(5):24-8. (In Russ.)

22. Markelova E.V., Guschina Ya.S., Kostinov M.P., Zhuravleva N.V. Clinical and immunological effect of vaccination with "PNEUMONIA 23" in children with atopic bronchial asthma. Journal of Microbiology, Epidemiology and Immunobiology. 2005;(2):83-5. (In Russ.)

23. Kostinov M.P., Ozeretskovsky N.A. Clinical and immunological efficacy of immunobiological drugs. Guide. Moscow: Miklos, 2004. 256 p. (In Russ.)

24. Kostinov MP, Cherdantsev AP, Savisko AA, et al. True and false reactions to the introduction of the flu vaccine in pregnant women. Issues of gynecology, obstetrics and perinatology. 2011;10(6):44-8. (In Russ.)

25. Magarshak OO, Kostinov MP. Problems of vaccination of children with allergic diseases. The attending physician. 2008;(9):44-8. (In Russ.)

26. Cherdantsev AP, Kostinov, MP, Kuselman AI. Vaccination of influenza in pregnant women. A guide for doctors. Moscow: MDV Group, 2014. 112 p. (In Russ.)

27. Cherdantsev AP, Kostinov MP, Kuselman AI. Vaccination of pregnant women against influenza and other infectious diseases. A guide for doctors. 3rd ed. Moscow: MDV Group, 2018. 143 p. (In Russ.)

28. Rudakova AV, Briko NI, Lobzin YuV, et al. Cost-effectiveness of vaccination against pneumococcal infection in adults at risk within the framework of federal and regional programs. Journal of Infectology. 2019;11(4):6-18. (In Russ.)

29. Committee on Infectious Diseases, O’Leary ST, Campbell JD, Ardura MI, et al. Recommendations for Prevention and Control of Influenza in Children, 2024-2025: Policy Statement. Pediatrics. 2024;154(4):e2024068507.

30. Wall DJ, Patel MM, Chung JR, et al. Antibody Response and Protection After Receipt of Inactivated Influenza Vaccine: A Systematic Review. Pediatrics. 2021;147(6): e2020019901.

31. Shi Y, Yang W, Li X, et al. Immunogenicity and Safety of One versus Two Doses of Quadrivalent Inactivated Influenza Vaccine (IIV4) in Vaccine-Unprimed Children and One Dose of IIV4 in Vaccine-Primed Children Aged 3-8 Years. Vaccines. 2023; 11(10):1586.

32. Cordero E, Roca-Oporto C, Bulnes-Ramos A, et al. Two Doses of Inactivated Influenza Vaccine Improve Immune Response in Solid Organ Transplant Recipients: Results of TRANSGRIPE 1-2, a Randomized Controlled Clinical Trial. Clinical Infectious Diseases. 2017;64(7):829-38.

33. Chuchalin AG, Avdeev SN, Aisanov ZR, et al. Russian Respiratory Society. Federal clinical guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease. Pulmonology. 2014;3:15-54. (In Russ.)

34. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD. 2019. 139 p.

35. Tkacheva ON, Kotovskaya SE, Kostinov MP, et al. Vaccination of the elderly and senile: Methodological recommendations. Vol. Version 1. M., 2020. 48 p. (In Russ.)

36. Son IM. Medical and demographic indicators of the Russian Federation in 2018. Statistical collection. Moscow, 2019. 253 p. (In Russ.)

37. Korshunov VA, Briko NI, Polybin RV, et al. Vaccination coverage against pneumococcal infection in adult risk groups in the Russian Federation. Epidemiology and vaccine prevention. 2024;23(6):13-23. (In Russ.)

38. Centers for Disease Control and Prevention (CDC). Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices — United States, 2013-2014. MMWR Recomm Rep. 2013;45(62):906.

39. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2008;(1):CD000422. doi:10.1002/14651858.CD000422.pub2. Update in: Cochrane Database Syst Rev. 2013;(1): CD000422. doi:10.1002/14651858.CD000422.pub3.

40. Loddenkemper R, Gibson GJ, Sibille Y.The burden of lung disease in Europe: data from the first European White Book. Breathe. 2004;1(1):7-9.

41. Baranov AA, Namazova-Baranova LS, Briko NI, et al. Vaccinoprophylaxis of pneumococcal infection in children and adults Methodological recommendations. Moscow: Limited Liability Company Publishing House "Pediatrician", 2023. 92 p. (In Russ.) EDN: WMDKYB.

42. Avdeev SN, Alyeva MH, Baranov AA, et al. Vaccinoprophylaxis of pneumococcal infection in children and adults. Methodological recommendations. Preventive medicine. 2023;26(9):3-23. (In Russ.)

43. Briko NI, Korshunov VA, Lobzin YuV, et al. Ten years of experience in the use of 13-valent conjugated polysaccharide pneumococcal vaccine in the Russian Federation. Epidemiology and vaccine prevention. 2023;(4):106-39. (In Russ.)

44. Cannon K, Elder C, Young M, et al. A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination. Vaccine. 2021;39(51):7494-502.

45. Klein NP, Peyrani P, Yacisin K, et al. A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age. Vaccine. 2021;39(38):5428-35.

46. Rockwell PG. ACIP approves 2023 child/adolescent and adult immunization schedules. American Family Physician. 2023;107(3):319-22.

47. Bass AR, Chakravarty E, Akl EA, et al. 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis Care Res (Hoboken). 2023;75(3):449-64.

48. Kobayashi M, Leidner AJ, Gierke R, et al. Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024. MMWR Morb Mortal Wkly Rep. 2025;74(1):1-8.

49. Horberg M, Thompson M, Agwu A, et al. Primary Care Guidance for Providers Who Care for Persons With Human Immunodeficiency Virus: 2024 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clinical Infectious Diseases. 2024:ciae479. doi:10.1093/cid/ciae479. Epub ahead of print.

50. Kamboj M, Bohlke K, Baptiste DM, et al. Vaccination of Adults With Cancer: ASCO Guideline. J Clin Oncol. 2024;42(14):1699-721.

51. Ignatova GL, Antonov VN, Blinova EV. Analysis of the effectiveness of combined or sequential vaccination with pneumococcal and influenza vaccines in patients with chronic obstructive pulmonary disease. Therapeutic Archive. 2019;91(8):12-7. (In Russ.)

52. Demko IV, Korchagin EE, Gordeeva NV, et al. An experience of vaccination against pneumococcal infection of adults at Krasnoyarsk krai. Pulmonologiya. 2017;27(1):21- 8. (In Russ.) doi:10.18093/0869-0189-2017-27-1-21-28.

53. Baldo V, Cocchio S, Gallo T, et al. Pneumococcal Conjugated Vaccine Reduces the High Mortality for Community-Acquired Pneumonia in the Elderly: an Italian Regional Experience. Bueno V, редактор. PLoS ONE. 2016;11(11):e0166637.

54. McLaughlin JM, Jiang Q, Isturiz RE, et al. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design. Clinical Infectious Diseases. 2018;67(10): 1498-506.

55. Bonten MJM, Huijts SM, Bolkenbaas M, et al. Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults. N Engl J Med. 2015;372(12):1114-25.

56. Ignatova GL, Avdeev SN, Antonov VN, et al. Vaccination against pneumococcal infection as a tool to reduce mortality in patients with COPD and IHD. Bulletin Physiology and Pathology of Respiration. 2024;(94):8-19. (In Russ.) doi:10.36604/1998-5029-2024-94-8-19. EDN: LLBJJZ.

57. Rudakova AV, Briko NI, Lobzin YuV, et al. Pharmacoeconomic effectiveness of vaccination of elderly citizens against pneumococcal infection in the Russian Federation. Preventive medicine. 2021;24(12):41-8. (In Russ.)

58. Rudakova AV, Briko NI, Lobzin YuV, et al. Pharmacoeconomic effectiveness of vaccination against pneumococcal infection in patients with chronic heart failure. Kardiolodija. 2023;63(5):19-26. (In Russ.)

59. Rudakova AV, Briko NI, Lobzin YuV, et al. Pharmacoeconomic effectiveness of vaccination against pneumococcal infection in patients with diabetes mellitus. Epidemiology and vaccine prevention. 2022;21(5):78-88. (In Russ.)

60. Recommendations to assure the quality, safety and efficacy of recombinant hepatitis B vaccines. WHO Technical Report Series. 2013. 978 p.

61. Brico NI. Assessment of the quality and effectiveness of immunoprophylaxis. The attending physician. 2012;(10):57. (In Russ.)

62. Bruce MG, Bruden D, Hurlburt D, et al. Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose. J Infect Dis. 2016;214(1):16-22.

63. Masseria C, Krishnarajah G.The estimated incidence of pertussis in people aged 50 years old in the United States, 2006-2010. BMC Infect Dis. 2015;15(1):534.

64. Bellini WJ, Rota JS, Lowe LE, et al. Subacute Sclerosing Panencephalitis: More Cases of This Fatal Disease Are Prevented by Measles Immunization than Was Previously Recognized. J INFECT DIS. 2005;192(10):1686-93.

65. Hardie DR, Albertyn C, Heckmann JM, Smuts HE. Molecular characterisation of virus in the brains of patients with measles inclusion body encephalitis (MIBE). Virol J. 2013;10(1):283.

66. Ivancic-Jelecki J, Baricevic M, Šantak M, et al. The first genetic characterization of a D4 measles virus strain derived from a patient with subacute sclerosing panencephalitis. Infection, Genetics and Evolution. 2013;17:71-8.

67. Jiang DP, Ide YH, Nagano-Fujii M, et al. Single-point mutations of the M protein of a measles virus variant obtained from a patient with subacute sclerosing panencephalitis critically affect solubility and subcellular localization of the M protein and cell-free virus production. Microbes and Infection. 2009;11(4):467-75.

68. Hotta H, Nihei K, Abe Y, et al. Full-Length Sequence Analysis of Subacute Sclerosing Panencephalitis (SSPE) Virus, a Mutant of Measles Virus, Isolated from Brain Tissues of a Patient Shortly after Onset of SSPE. Microbiology and Immunology. 2006;50(7): 525-34.

69. Miki K, Komase K, Mgone CS, et al. Molecular analysis of measles virus genome derived from SSPE and acute measles patients in Papua, New Guinea. Journal of Medical Virology. 2002;68(1):105-12.

70. Woelk CH, Pybus OG, Jin L, et al. Increased positive selection pressure in persistent (SSPE) versus acute measles virus infections. Journal of General Virology. 2002; 83(6):1419-30.

71. Federal Service for Supervision of Consumer Rights Protection and Human Welfare. On the state of sanitary and epidemiological welfare of the population in the Russian Federation in 2024: State Report. M., 2025. 424 p. (In Russ.) ISBN: 978-5-7508-2350-5.

72. Lo NC, Hotez PJ. Public Health and Economic Consequences of Vaccine Hesitancy for Measles in the United States. JAMA Pediatr. 2017;171(9):887.

73. Kostinov MP, Shmitko AD, Bocharova II, et al. The level of IgG antibodies to measles virus in the umbilical cord blood of newborns, taking into account the age of mothers. Epidemiology and infectious diseases. 2014;19(3):30-4. (In Russ.)

74. Kostinov MP, Filatov NN, Zhuravlev PI, et al. Age-related features of immunity to the measles virus in employees of a large hospital complex in a megalopolis. Pulmonology. 2018;28(6):701-7. (In Russ.)

75. Kostinov MP, Filatov NN, Zhuravlev PI, et al. The level of collective immunity to the measles virus among employees of a separate hospital within the framework of the state measles elimination program. Infection and immunity. 2020;10(1):129-36. (In Russ.)

76. Solovyova, I.L., Kostinov, M.P., Kuselman AI. et al. Features of vaccination of children with an altered premorbid background against hepatitis B, measles, and mumps. Ulyanovsk: UlSU, 2006. 296 p. (In Russ.)

77. Polishchuk WB, Ryzhov AA, Kostinov MP, et al. The state of anti-acne immunity in patients on the lung transplant waiting list. Journal of Microbiology, Epidemiology and Immunobiology. 93(4):55-60. (In Russ.)

78. Viral Infections of Humans: Epidemiology and Control. Kaslow RA, Stanberry LR, Le Duc JW (eds.), Boston, MA: Springer US; 2014. XVI, 1215 p. ISBN: 978-1-4899-7447-1. doi:10.1007/978-1-4899-7448-8.

79. Babichenko IV, Ibragimova OM. Clinical recommendations (treatment protocol) for providing medical care to children with mumps. Moscow: FSBI NIIDI FMBA of Russia, 2015. 27 p. (In Russ.)

80. Yushchuk ND, Vengerov SE. Infectious diseases: national guidelines. 2nd ed. Moscow: GEOTAR-Media, 2018. 1104 p. (In Russ.)

81. Kostinov MP. Fundamentals of vaccine prevention in children with chronic pathology. Moscow: Medicine for all, 2002. 320 p. (In Russ.)

82. Yuminova NV. The current state of mumps vaccine prevention in Russia. Epidemiology and vaccine prevention. 2002;(2):21-5. (In Russ.)

83. Baranov AA, Kostinov AM, Kovtun OP, et al. Strategies for the control of chickenpox in Russia. Results of the international meeting of the Expert Council on the prevention of chickenpox (W.A.V.E.). Issues from the field of pediatrics. 2010;9(3):5- 12. (In Russ.)

84. Koroleva IS, Koroleva MA, Churilova NS, et al. Meningococcal infection in modern realities. Epidemiology and infectious diseases are topical issues. 2023;13(2):34-9. (In Russ.)

85. Davydenko MA, Churilova NS, Koroleva IS. Epidemiological manifestations of purulent bacterial meningitis in the Russian Federation. Epidemiology and vaccine prevention. 2024;23(5):33-41. (In Russ.)

86. Friedman YVES, Harith SM. Prevention of meningococcal infection. Medical advice. 2017;(4):16-8. (In Russ.)

87. Kim YR, Hyun H, Kim EJ, et al. Effectiveness of quadrivalent meningococcal conjugate vaccine against meningococcal carriage and genotype character changes: A secondary analysis of prospective cohort study in Korean military trainees. International Journal of Infectious Diseases. 2024;146:107150.

88. Forcier M, Musacchio N. An overview of human papillomavirus infection for the dermatologist: disease, diagnosis, management, and prevention: Overview of HPV for the dermatologist. Dermatologic Therapy. 2010;23(5):458-76.

89. Brown DR, Shew ML, Qadadri B, et al. A Longitudinal Study of Genital Human Papillomavirus Infection in a Cohort of Closely Followed Adolescent Women. J INFECT DIS. 2005;191(2):182-92.

90. Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine. 2006;24:S42-51.

91. Cutts F. Human papillomavirus and HPV vaccines: a review. Bull World Health Organ. 2007;85(09):719-26.

92. Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Health. 2020;8(2):e191-203.

93. Pandhi D, Sonthalia S. Human papilloma virus vaccines: Current scenario. Indian J Sex Transm Dis. 2011;32(2):75.

94. Murillo R, Ordóñez-Reyes C. Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs. International Journal of Gynecological Cancer. 2019;29(8):1317-26.

95. Podymova DM, Azov AG. Viral hepatitis in elderly patients. Features of epidemiology, clinical picture, prevention and treatment. Viral hepatitis: achievements and prospects. 2001;(1):3-4. (In Russ.)

96. Shumilov VI, Shevtsov VA, Lobastov SP. Experience in studying the antigenic activity of inactivated hepatitis A vaccines. Military Medical Journal. 2001;(12):52. (In Russ.)

97. Dagan R. Incidence of Hepatitis A in Israel Following Universal Immunization of Toddlers. JAMA. 2005;294(2):202.

98. Shevtsov VA, Volgin AR. Efficacy and safety of vaccines for the prevention of hepatitis A.Immunology. 2015;36(4):227-30. (In Russ.)

99. Movsesyants AA, Olefir SE. Modern problems of rabies vaccination prevention. Biological products. Prevention, diagnosis, and treatment. 2019;19(1):10-6. (In Russ.)

100. Hampson K, Coudeville L, Lembo T, et al. Estimating the Global Burden of Endemic Canine Rabies. Carvalho MS, редактор. PLoS Negl Trop Dis. 2015;9(4):e0003709.

101. Lobzin YuV, Volzhanin VM, Kovalenko AN. Typhoid fever: the current state of the problem. Clinical microbiology and antimicrobial chemotherapy. 2005;7(1):47-67. (In Russ.)

102. Stoner MC, Forsythe R, Mills AS, et al. Intestinal perforation secondary to Salmonella typhi: case report and review of the literature. Am Surg. 2000;66(2):219-22.

103. Lin FY, Vo AH, Phan VB, et al. The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam. Am J Trop Med Hyg. 2000;62(5):644-8.

104. Sinha A, Sazawal S, Kumar R, et al. Typhoid fever in children aged less than 5 years. Lancet. 1999;354(9180):734-7.

105. Ivanoff B. Typhoid fever: global situation and WHO recommendations. Southeast Asian J Trop Med Public Health. 1995;26(Suppl 2):1-6.

106. Tsinserling VA, Kovalenko AN, Baykov VV. Analysis of lethal outcomes of typhoid fever. Pathology archive. 2007;(1):3640. (In Russ.)

107. Engels EA, Lau J. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev. 2000;(2):CD001261. doi: 10.1002/14651858.CD001261. Update in: Cochrane Database Syst Rev. 2007;(3):CD001261. doi:10.1002/14651858.CD001261.pub2.

108. Pegues D, Ohl M, Miller S. Salmonella species, including Salmonella Typhi. In: Mandell G.L., Bennett J.E., Dolin R., editors. Principles and practice of infectious diseases. 6th ed. New York: Churchill Livingstone, 2004. 2636-2654 с.

109. Parry CM, Hien TT, Dougan G, et al. Typhoid Fever. N Engl J Med. 2002;347(22):1770-82.

110. Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine. 1996;14(5):435-8.

111. Henao-Restrepo AM, Camacho A, Longini IM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). The Lancet. 2017;389(10068):505-18.

112. Gsell PS, Camacho A, Kucharski AJ, et al. Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report. The Lancet Infectious Diseases. 2017;17(12):1276-84.

113. Vachaev BF, Yagovkin EA, Ananyina YuV, et al. Prospects of application and improvement of leptospirosis vaccine for humans. Epidemiology and vaccine prevention. 2012;65(4):68-72. (In Russ.)

114. Haake DA, Levett PN. Leptospirosis in Humans. In: Adler B. (eds) Leptospira and Leptospirosis. Current Topics in Microbiology and Immunology. Berlin.Heidelberg.: Springer, 2015. 387 p.

115. Costa F, Hagan JE, Calcagno J, et al. Global Morbidity and Mortality of Leptospirosis: A Systematic Review. Small PLC, редактор. PLoS Negl Trop Dis. 2015;9(9):e0003898.

116. Longwin FW, Kondratenko FW, Vodyanitskaya SY. Anthrax in the world, CIS countries and the Russian Federation (literature review). Medical Bulletin of the South of Russia. 2017;(3):17-22. (In Russ.)

117. Yeremenko YEI, Ryazanova AG, Buravtseva NP. The current situation of anthrax in Russia and the world. Main trends and features. Problems of particularly dangerous infections. 2017;(1):65-71. (In Russ.)

118. Mikshis NI, Kutyrev V. The current state of the problem of developing vaccines for specific plague prevention. Problems of particularly dangerous infections. 2019;(1):50-64. (In Russ.)

119. Healthcare in Russia. Moscow: Stat.sat./Rosstat., 2019. 170 p. (In Russ.)

120. Sayapina LV, Solovyov EA, Goryaev AA, Bondarev VP. To study the immunobiological properties of the Francisella tularensis 15 NIIEG vaccine strain under long-term storage conditions. Problems of particularly dangerous infections. 2015;(2):87-91. (In Russ.)

121. Govorunov IG. The tularemia epidemic in the Russian Federation in 2017-2019. International Scientific Conference SCVRT2019 "Situational centers and information and analytical systems of class 4i for monitoring and security tasks": SCVRT2019 Proceedings of the International Scientific Conference, Pushchino, November 13, 2019. Pushchino: Scientific Research Center for Physical and Technical Informatics, 2019. cc. 84-89. (In Russ.) EDN: IWBGXS.

122. Sayapina LV, Bondarev VP, Olefir SE. The current state of vaccination prevention of particularly dangerous infections. Biotechnology, immunology. 2016;(2):107-10. (In Russ.)

123. Ryan ET, Dhar U, Khan WA, et al. Mortality, morbidity, and microbiology of endemic cholera among hospitalized patients in Dhaka, Bangladesh. Am J Trop Med Hyg. 2000;63(1):12-20.

124. Ali M, Nelson AR, Lopez AL, Sack DA. Updated Global Burden of Cholera in Endemic Countries. Remais JV, редактор. PLoS Negl Trop Dis. 2015;9(6):e0003832.

125. Kutyrev VV, Devdariani ZL, Sayapina LV. The current state of scientific research in the field of vaccine prevention of particularly dangerous bacterial infections. Problems of particularly dangerous infections. 2006;92(2):18-24. (In Russ.)

126. Shchukovskaya TN, Sayapina LV, Kutyrev BB. Cholera vaccine prevention: the current state of the issue. Epidemiology and vaccine prevention. 2009;45(2):62-7. (In Russ.)

127. Popova AY, Kutyrev BB, Balakhonov SV, et al. Coordination of anti-plague institutions of Rospotrebnadzor for the rehabilitation of the Gorno-Altaisk highland natural plague outbreak in 2016. Problems of particularly dangerous infections. 2016;(4):5- 10. (In Russ.)

128. Popov NV, Matrosov AN, Knyazeva TV, et al. Epizootic activity of natural plague foci of the Russian Federation in 2016, forecast for 2017 Problems of particularly dangerous infections. 2017;(1):5-12. (In Russ.)

129. Dobrokhotova YUE, Gankovskaya LV, Bakhareva IV, et al. The role of immune mechanisms in the pathogenesis of miscarriage. Obstetrics and gynecology. 2016;(7):5- 10. (In Russ.)

130. Steinborn A, Schmitt E, Kisielewicz A, et al. Pregnancy-associated diseases are characterized by the composition of the systemic regulatory T cell (Treg) pool with distinct subsets of Tregs. Clinical and Experimental Immunology. 2011;167(1):84-98.

131. Warning JC, McCracken SA, Morris JM. A balancing act: mechanisms by which the fetus avoids rejection by the maternal immune system. REPRODUCTION. 2011;141(6):715-24.

132. Sevostyanova OY, Teplova SN, Radzinsky VE. Immune homeostasis in the dynamics of uncomplicated pregnancy. Bulletin of the RUDN University of Medicine, Obstetrics and Gynecology. 2005;32(4):39-42. (In Russ.)

133. Rebrov B.A., Rebrova O.A., Komarov E.B. Symposium "Pneumonia in pregnant women". Medical and pharmacy news. 2011;18:387. (In Russ.)

134. Tarbayeva DA, Kostinov MP, Zagorodnaya ED, et al. Obstetric and perinatal outcomes of pregnancy complicated by acute respiratory infection in the second trimester of gestation. Obstetrics and gynecology. 2012;(2):67-71. (In Russ.)

135. Tarbaeva DA, Kostinov MP, Iozefson SA, Zagorodnaya ED. Clinical course and outcomes of influenza A (H1N1) 2009 in pregnant women. Journal of Microbiology, Epidemiology and Immunology. 2011;(4):71-6. (In Russ.)

136. Kuzmin VN. The problem of the H1N1 influenza virus and the features of the disease in women during pregnancy. The attending physician. 2010;(1):66-8. (In Russ.)

137. Siston AM. Pandemic 2009 Influenza A(H1N1) Virus Illness Among Pregnant Women in the United States. JAMA. 2010;303(15):1517.

138. Belokrinitskaya TE, Tarbaeva DA, Trubitsyna AYu, et al. Features of the course of swine flu in dead pregnant women and in cases that almost ended in death. The attending physician. 2013;(3):31-6. (In Russ.)

139. Ortiz JR, Englund JA, Neuzil KM. Influenza vaccine for pregnant women in resourceconstrained countries: A review of the evidence to inform policy decisions. Vaccine. 2011;29(27):4439-52.

140. The ANZIC Influenza Investigators and Australasian Maternity Outcomes Surveillance System. Critical illness due to 2009 A/H1N1 influenza in pregnant and postpartum women: population based cohort study. BMJ. 2010;340(mar18 3):c1279-c1279.

141. Pebody RG, McLean E, Zhao H, et al. Pandemic Influenza A (H1N1) 2009 and mortality in the United Kingdom: risk factors for death, April 2009 to March 2010. Euro Surveill. 2010;15(20):19571.

142. Kostinov MP, Cherdantsev AP. Clinical and immunological safety of inactivated immunoadjuvant subunit influenza vaccine for pregnant women. Obstetrics and gynecology. 2016;(2):64-9. (In Russ.)

143. Shmitko AD, Novikova SV, Bocharova II, et al. Mechanisms and factors influencing the transplacental transmission of IgG class antibodies in the mother-placenta-fetus system. Russian Bulletin of the obstetrician-gynecologist. 2014;14(6):27-31. (In Russ.)

144. Bocharova II, Kostinov MP, Novikova SV, et al. Transplacental antibodies to measles virus in newborns with different pregnancy course in their mothers. Russian Bulletin of the obstetrician-gynecologist. 2014;14(2):14-8. (In Russ.)

145. American College of Obstetricians and Gynecologists. ACOG Committee Opinion. Immunization during pregnancy. Obstet Gynecol. 2003;101(1):207-12. doi:10.1016/s0029-7844(02)02738-2.

146. Kostinov MP, Cherdantsev AP, Kuselman AI, et al. Prospective randomized openlabel comparative study of immunogenicity after subunit and polymeric subunit influenza vaccines administration among mothers and infants. Human Vaccines & Immunotherapeutics. 2018;14(12):2971-8.

147. Cherdantsev AP, Kostinov MP, Kuselman AI, et al. Immunity to influenza virus in newborns after vaccination of women during pregnancy with subunit immunoadjuvant and non-adjuvant drugs. G.N. Speransky Pediatrics journal. 2018;97(1):100- 5. (In Russ.)

148. Cherdantsev AP, Kostinov MP, Kuselman AI, et al. Analysis of the ante- and postnatal development of children against the background of vaccination of pregnant women against influenza. Russian Bulletin of Perinatology and Pediatrics. 2013;58(2):30-4. (In Russ.)

149. Kostinov MP, Cherdantsev AP. The state of health of infants born to pregnant women vaccinated against influenza. Pediatrics. 2016;95(1):67-71. (In Russ.)

150. Kostinov MP, Cherdantsev AP, Akhmatova NK, et al. Immunogenicity and safety of subunit influenza vaccines in pregnant women. ERJ Open Res. 2018;4(2):00060-2017.

151. Kostinov MP, Pakhomov DV, Magarshak OO, Sukhinin MV. Vaccination of pneumococcal infection as one of the causes of complications and mortality in influenza. Issues of modern pediatrics. 2009;8(6):131-4. (In Russ.)

152. Makris MC, Polyzos KA, Mavros MN, et al. Safety of Hepatitis B, Pneumococcal Polysaccharide and Meningococcal Polysaccharide Vaccines in Pregnancy: A Systematic Review. Drug Safety. 2012;35(1):1-14.

153. Laibl VR, Sheffield JS. Influenza and Pneumonia in Pregnancy. Clinics in Perinatology. 2005;32(3):727-38.

154. Salam RA, Das JK, Dojo Soeandy C, et al. Impact of Haemophilus influenzae type B (Hib) and viral influenza vaccinations in pregnancy for improving maternal, neonatal and infant health outcomes. Cochrane Database Syst Rev. 2015;2015(6):CD009982. doi:10.1002/14651858.

155. Liang JL, Tiwari T, Moro P, et al. Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2018;67(2):1-44.

156. Amirthalingam G, Andrews N, Campbell H, et al. Effectiveness of maternal pertussis vaccination in England: an observational study. The Lancet. 2014;384(9953):1521-8.

157. Dabrera G, Amirthalingam G, Andrews N, et al. A Case-Control Study to Estimate the Effectiveness of Maternal Pertussis Vaccination in Protecting Newborn Infants in England and Wales, 2012-2013. Clinical Infectious Diseases. 2015;60(3):333-7.

158. Baxter R, Bartlett J, Fireman B, et al. Effectiveness of Vaccination During Pregnancy to Prevent Infant Pertussis. Pediatrics. 2017;139(5):e20164091.

159. McMillan M, Clarke M, Parrella A, et al. Safety of Tetanus, Diphtheria, and Pertussis Vaccination During Pregnancy: A Systematic Review. Obstetrics & Gynecology. 2017; 129(3):560-73.

160. Committee Opinion No. 718: Update on Immunization and Pregnancy: Tetanus, Diphtheria, and Pertussis Vaccination. Obstetrics & Gynecology. 2017;130(3):e153-7.

161. Prutskova EV, Cherdantsev AP, Andreeva NP. Vaccines and vaccination against whooping cough in children and adults. Infectious diseases: news, opinions, education. 2018;14(2):71-7. (In Russ.)

162. Cherdantsev AP, Kostinov, MP, Shmitko AD, Cherdantseva AA. Vaccination of pregnant women against controlled respiratory tract infections. Journal of Infectology. 2020;12(2):30-7. (In Russ.)

163. Cherdantsev AP, Prutskova EV, Kostinov MP. New possibilities of pertussis vaccine prophylaxis. Childhood infections. 2020;19(2(71)):58-63. (In Russ.)

164. Drapkina OM, Avdeev SN, Briko NI, et al. Vaccination during the COVID-19 pandemic. Methodological recommendations. Moscow: ROPNIZ, LLC "Silicea-Polygraph"; 2022. 96 p. (In Russ.)

165. Kostinov MP, Kvasova MA, Tarasova AA, et al. The impact of COVID-19 on pregnancy outcome and evaluation of SARS-Cov-2 vaccine prophylaxis in pregnant and lactating women. G.N. Speransky Pediatrics journal. 2022;101(1):128-34. (In Russ.)

166. Kostinov MP, Prutskova EV, Cherdantsev AP, et al. The level of total IgE and pertussis antibodies in revaccinated adolescents depends on the development of local and systemic reactions. Medical Bulletin of the Ministry of Internal Affairs. 2024;131(4):88- 91. (In Russ.)

167. Clark LR, Johnson DR. Safety and Clinical Benefits of Adacel® and Adacel®- Polio Vaccination in Pregnancy: A Structured Literature Review. Infect Dis Ther. 2023;12(8):1955-2003.

168. Kostinov MP, Adamyan LV, Cherdantseva AP, Ozeretsky NA. Vaccination and emergency immunoprophylaxis of infectious diseases in pregnant and lactating women. Moscow: MDV Group; 2022. 98 p. (In Russ.)

169. Zarochentseva NV, Baranov II, Kostinov MP, Bashankaeva Yu N. Immunization of women in different age periods. Doctor.ru. 20(8):70-8. (In Russ.)

170. Kostinov MP, Cherdantsev AP, Ozeretskovsky NA, Nikityuk SF. Immunoprophylaxis of infectious diseases in women during pregnancy and breastfeeding. Infectious diseases: news, opinions, education. 2023;12:73-9. (In Russ.)

171. Kostinov MP, Cherdantsev AP. Specific prevention of controlled respiratory infections in pregnant women. Respiratory medicine: a 5-volume manual. Edited by A.G. Chuchalin, 3rd ed., supplement and revision. Moscow: Pulmomedia; 2024. 537 p. (In Russ.)

172. Azarov II, Butakov SS, Shpuntov AA. Ensuring sanitary and epidemiological welfare in the Armed Forces of the Russian Federation in 2017. Public health and habitat. 2018;1(298):15-9. (In Russ.)

173. Shubin IV. The relevance of vaccinoprophylaxis of pneumococcal infection in organized groups of military personnel. Bulletin of modern Clinical Medicine. 2017;10(1):36-42. (In Russ.)

174. Zhdanov KV, Zakharenko SM, Ivanov KS,et al. Problems of meningococcal infection vaccination in the Armed Forces. Military Medical Journal. 2021;342(6):36-42. (In Russ.)

175. Millar BC, Moore PJA, Moore JE. Meningococcal disease: has the battle been won? J R Army Med Corps. 2017;163(4):235-41.

176. Belevitin AB, Akimkin VG, Mosyagin VD, et al. Organizational and epidemiological aspects of community-acquired pneumonia prevention in military groups. Military Medical Journal. 2009;330(9):56-63. (In Russ.)

177. Kostinov MP, Tatevosov BP, Protasov AD, et al. Vaccination against Staphylococcus aureus and some representatives of the Enterobacteriaceae family in the complex treatment of community-acquired mild pneumonia in newly recruited military personnel. Medical Bulletin of the Ministry of Internal Affairs. 2021;115(6):23-9. (In Russ.)

178. Tatevosov BP, Shubin IV, Kostinov MP, Chuchalin AG. Evaluation of the results of vaccine therapy in the complex treatment of community-acquired pneumonia in young people in organized groups. Medical Bulletin of the Ministry of Internal Affairs. 2013;67(6):60-3. (In Russ.)

179. Kostinov MP, Zverev BB, Svitich OA, Mukhachev IS. Vaccination of persons subject to conscription. Epidemiology and vaccine prevention. 2023;5(22):58-62. (In Russ.)

180. Kostinov MP, Zverev BB, Svitich OA. Vaccination of persons subject to conscription and entering the military service contract. A guide for doctors. Edited by Moscow: MDV Group, 2024. 56 p. (In Russ.)

181. Prutskova EV, Cherdantsev AP, Kostinov MP, et al. The clinical course of the postvaccination period in children who were vaccinated with different types of pertussis vaccines. G.N. Speransky Pediatrics journal. 2020;99(1):117-20. (In Russ.)

182. Kostinov MP, Prutskova EV, Cherdantsev AP, et al. Safety of pertussis vaccines in adolescents. Journal of Infectology. 12(4):29-36. (In Russ.)

183. Prutskova EV, Cherdantsev AP, Kostinov MP. Immunological aspects of additional revaccination of adolescents against whooping cough, diphtheria and tetanus. Russian Bulletin of Perinatology and Pediatrics. 2023;68(4):77-81. (In Russ.)

184. Kostinov MP, Simonova EG, Filatov NN. Epidemiology and vaccination of influenza in the context of COVID-19. A training manual for additional professional education of doctors. Moscow: Geotar-Media Publishing Group, LLC, 2021. 112 p. (In Russ.)

185. Kostinov MP. Vaccine prevention of COVID-19 in patients with comorbid diseases. A guide for doctors. Edited by Moscow: MDV Group; 2022. 176 p. (In Russ.)

186. Kozlov RS, Avdeev SN, Briko NI, et al. Vaccination of pneumococcal infections in adults. Resolution of the Council of Experts (Moscow, December 16, 2017). Clinical microbiology and antimicrobial chemotherapy. 2017;20(1):5-8. (In Russ.)

187. Avdeev SN, Dehnich AB, Zaitsev AA, et al. Community-acquired pneumonia: federal clinical guidelines for diagnosis and treatment. Pulmonology. 2022;(3):295-355. (In Russ.)

188. Ovchinnikov SW, Zaitsev AA, Sinopalnikov AI. Diagnosis, treatment and vaccination of community-acquired pneumonia in military personnel. Guidelines for the treatment of community-acquired pneumonia in military personnel. Moscow: N.N. Burdenko State Pedagogical University, 2015. 61 p. (In Russ.)

189. Zaitsev AA, Akimkin VG, Briko NI, and others. Epidemiology and vaccine prevention of pneumococcal infections in military personnel. Military Medical Journal. 2019; 340(1):39-45. (In Russ.)

190. Kostinov MP. From preventive to therapeutic effect of vaccines against pneumococcal and hemophilic type b infections in patients with bronchopulmonary pathology. Edited by Moscow: All-Russian Foundation for Human Health, 2007. 82 p. (In Russ.)

191. Leidner AJ, Murthy N, Chesson HW, et al. Cost-effectiveness of adult vaccinations: A systematic review. Vaccine. 2019;37(2):226-34.

192. Rudakova AV, Harit SM, Uskov AN, Lobzin SW. Analysis of the cost effectiveness of flu vaccination for working-age citizens. Medicine of extreme situations. 2016;56(2):25-36. (In Russ.)

193. Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1(1):ofu024.

194. Rudakova AV, Briko NI, Lobzin YuV, and others. Adult vaccination against pneumococcal infection in the Russian Federation: social and pharmacoeconomic aspects. Journal of Infectology. 2018;10(3):11-22. (In Russ.)

195. Ignatova GL, Antonov VN. Analysis of the effect of vaccination against pneumococcal infection on the course of comorbid pathology in patients with chronic obstructive pulmonary disease and chronic heart failure. Therapeutic Archive. 2018;90(8):53-62. (In Russ.)

196. Kostinov MP. Adult vaccination: a personalized approach. Q: A guide for doctors. Moscow: GEOTAR-Media; 2024. p. 192. (In Russ.)